Cytokinetics, Incorporated
CYTK
$59.73
-$0.27-0.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.15% | -30.45% | -11.19% | -15.96% | -12.03% |
| Total Depreciation and Amortization | 6.23% | -28.45% | -27.44% | -23.23% | -19.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 102.40% | 151.76% | 69.86% | 51.43% | 53.14% |
| Change in Net Operating Assets | -199.90% | -79.57% | -115.50% | 1,732.62% | 1,054.55% |
| Cash from Operations | -28.83% | -7.07% | -6.98% | 5.59% | 4.45% |
| Capital Expenditure | -535.10% | -659.49% | -433.45% | -843.79% | -175.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 107.55% | 129.51% | 137.83% | -537.77% | -328.19% |
| Cash from Investing | 103.01% | 126.66% | 135.81% | -550.94% | -331.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4,199.37% | -5,873.22% | -168.06% | -630.89% | -1,020.98% |
| Issuance of Common Stock | -95.27% | -96.98% | -97.05% | 113.13% | 315.92% |
| Repurchase of Common Stock | 87.43% | 86.83% | 90.74% | 93.52% | -86.66% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -12.50% | -62.50% | -70.00% | 300.00% | 300.00% |
| Cash from Financing | -43.64% | -62.07% | -92.24% | 150.26% | 320.49% |
| Foreign Exchange rate Adjustments | -442.11% | -496.12% | -3,517.39% | -1,357.14% | 1,145.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 267.34% | 443.38% | -193.80% | -370.18% | -139.31% |